mRNA |
Erlotinib |
gCSI |
pan-cancer |
AAC |
-0.026 |
0.6 |
mRNA |
alisertib:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.017 |
0.6 |
mRNA |
valdecoxib |
CTRPv2 |
pan-cancer |
AAC |
0.017 |
0.6 |
mRNA |
selumetinib:decitabine (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.016 |
0.6 |
mRNA |
trifluoperazine |
CTRPv2 |
pan-cancer |
AAC |
-0.018 |
0.6 |
mRNA |
ML210 |
CTRPv2 |
pan-cancer |
AAC |
0.016 |
0.6 |
mRNA |
selumetinib:vorinostat (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.017 |
0.6 |
mRNA |
Nilotinib |
CTRPv2 |
pan-cancer |
AAC |
-0.017 |
0.7 |
mRNA |
clofarabine |
CTRPv2 |
pan-cancer |
AAC |
-0.013 |
0.7 |
mRNA |
procarbazine |
CTRPv2 |
pan-cancer |
AAC |
-0.018 |
0.7 |